The first Actos lawsuit trial started this month in California over a man afflicted with bladder cancer after taking the popular diabetes drug. Already, it is producing shocking allegations about the lengths a drug company will go to protect profits.
Numerous health organizations from the FDA to Health Canada and the European Medicines Agency warned in 2011 that long-term use of Actos could be related to an increased risk of bladder cancer. France and Germany also banned new prescriptions.
However, court filings and testimony in the trial show Takeda Pharmaceuticals, the maker of the drug, may have known about the dangers years before, hidden them from doctors and consumers, and focused instead on keeping sales at a maximum.
As news spread of possible Actos bladder cancer side effects, thousands of affected patients cae forward. Takeda now faces around 1,200 lawsuits in a federal court and 1,800 in a California state court.
Months ago, lawyers representing victims filed evidence showing Takeda approached doctors in 2003 to ask if they would still prescribe a diabetes drug which had a label warning for bladder cancer. Experts believe this is a clear sign that the company knew of the risks but decided to conceal them to protect sales.
Now, as the first trial in California gets underway for a man dying of bladder cancer, a former pharmacologist for Takeda has testified of internal emails showing that as news spread of Actos bladder cancer risks in 2011, company executives were more concerned with manipulating regulatory agencies in order to maintain sales.
Lawyers are still helping those diagnosed with bladder cancer after taking Actos file an Actos lawsuit.
If you or a loved one have been affected, it is important to speak with a lawyer about your legal rights as soon as possible.
Due to the potential value and specialized nature of defective drug injury cases, DrugRisk only recommends lawyers and law firms who have already handled Actos lawsuits.
Contact us today for more information on Actos or to speak with a lawyer.